Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell™ Universal Donor Stem Cell Therapy for Brain Injury

Rhea-AI Summary

Therapeutics Solutions International (OTC Markets: TSOI) announced positive preclinical data showcasing its JadiCell therapy's superior neuro-regenerative capabilities compared to other cell therapies. Collaborators observed enhanced stem cell proliferation in the dentate gyrus regions of animal models and demonstrated neuron protection from inflammation-related cell death. The FDA has cleared JadiCell for clinical trials for other uses, and efforts are underway to file an Investigational New Drug application to initiate trials targeting Chronic Traumatic Encephalopathy, a serious condition affecting veterans.

Positive

• Demonstrated superior neuro-regenerative activity of JadiCell compared to mesenchymal stem cells.
• Observed stimulation of stem cell proliferation in the dentate gyrus.
• Protection of neurons against inflammation-related cell death.
• JadiCell cleared by the FDA for clinical trials in other indications.
• Plans to file an Investigational New Drug application for Chronic Traumatic Encephalopathy clinical trials.

Negative

• None.

OCEANSIDE, Calif., Sept. 28, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI), reported today positive preclinical data demonstrating superior neuro-regenerative activity to other cell therapies such as mesenchymal stem cells.  Using animal models, Company collaborators demonstrated stimulation of stem cell proliferation that reside in parts of the brain called the "dentate gyrus".  Additionally, the Company reported protection of neurons from inflammation associated cell death as well as reduction of inflammatory proteins produced by brain cells called "microglia".

"These data, combined with the fact that the JadiCell has already been cleared by the FDA for clinical trials in other indications, strongly support the development of the JadiCell as a therapeutic candidate for treatment of brain injuries, including chronic traumatic encephalopathy," said Dr. James Veltmeyer, Chief Medical Officer of the Company and San Diego Top Doctor. "We are working with our team and consultants to assemble the Investigational New Drug (IND) Application with the FDA to begin clinical trials on this terrible condition."

"Brain injury in the form of Chronic Traumatic Encephalopathy is a major scourge on the bravest elements of our society: the veterans. It is estimated that approximately 1 suicide per hour occurs because of PTSD," said Famela Ramos, Former Congressional Candidate and Director of Business Development for Therapeutic Solutions International. "The fact that we are able to offer hope for this terrible condition has our whole team energized."

"To our knowledge, we are the first Company to integrate a cell therapy approach towards combatting suicide," said Kalina O'Connor Director of the Campbell Neurosciences Division of TSOI.

"Through tireless work of our Scientific Advisory Board and our collaborators, we are pleased to be moving towards filing with the FDA to begin a clinical trial which is the first of its kind.  Currently there are no potentially curative approaches for Chronic Traumatic Encephalopathy," said Timothy Dixon, President and CEO of the Company.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com

ir@tsoimail.com

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-positive-preclinical-data-on-jadicell-universal-donor-stem-cell-therapy-for-brain-injury-301138937.html

SOURCE Therapeutic Solutions International

FAQ

What was reported by Therapeutics Solutions International on September 28, 2020 regarding TSOI?

Therapeutics Solutions International announced positive preclinical data for its JadiCell therapy, demonstrating superior neuro-regenerative activity compared to other cell therapies.

What is the significance of JadiCell's preclinical data for TSOI's future?

The preclinical data supports the development of JadiCell as a potential treatment for brain injuries, particularly Chronic Traumatic Encephalopathy.

Which condition is TSOI targeting with its JadiCell therapy?

TSOI is targeting Chronic Traumatic Encephalopathy, which is a significant issue among veterans.

What steps is TSOI taking to begin clinical trials for JadiCell?

TSOI is preparing to file an Investigational New Drug application with the FDA to initiate clinical trials.

What potential market impact does TSOI's JadiCell therapy have?

If successful, JadiCell therapy could fill a critical gap in the treatment of brain injuries, potentially benefiting a large population, especially veterans.